Business

A digital medicine company tries to adopt pharma’s patent game. Will it work?

By Rebecca Robbins @rebeccadrobbins

April 13, 2018

A screenshot from one of Akili's video games. Akili Interactive Labs

I

n biopharma, patents are everything. In tech? Not so much.

Which is why it was unusual to see a company that’s trying to turn software into medicine announce this week that it’s bagged several patents.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

What is STAT Plus?

About the Author

Rebecca Robbins
Business Reporter
Rebecca covers the business of biopharma.

Tags

Leave a Comment

Please enter your name.
Please enter a comment.

Trending
Epidiolex
Panel recommends FDA approval of epilepsy drug derived from…
Panel recommends FDA approval of epilepsy drug derived from marijuana
Gabacount
New on the streets: Gabapentin, a drug for nerve…
New on the streets: Gabapentin, a drug for nerve pain, and a new target of misuse
Pharmalot
How a patient advocacy group is used to promote…
How a patient advocacy group is used to promote an Insys drug and other fentanyl meds
Recommended
Vertex
U.K. ministers urge Vertex to reach pricing deal on…
U.K. ministers urge Vertex to reach pricing deal on its cystic fibrosis drug
Pharmalittle: Fresenius walks away from Akorn deal; FDA bounces…
Pharmalittle: Fresenius walks away from Akorn deal; FDA bounces a Pfizer biosimilar
Prothena scraps lead drug following mid-stage study failure
Prothena scraps lead drug following mid-stage study failure

Recommended Stories

Biotech

Prothena scraps lead drug following mid-stage study failure

By Adam Feuerstein

Adam's Take

SEC extends probe into Northwest Biotherapeutics as financial struggles mount

By Adam Feuerstein

Interacting chromatin chains
Biotech

Startup unwinds the role of chromatin to target epigenetic changes in cancer

By Elizabeth Cooney

Novartis International pharmaceutical
Biotech

For the first CAR-T therapy, early sales are weak but hopes are still sky high

By Damian Garde

Biotech

The Supreme Court decision that’s shaking up biotech

By Damian Garde

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.